Авторы

  • Yusupov A.F., Karimova M.Kh., Dzhamalova Sh.A., Jalalov A.K., Khaitboev N.Sh.

Ключевые слова:

neovascular glaucoma, proliferative diabetic retinopathy, micropulse trans-scleral cyclophotocoagulation, MP-TSCPC, intraocular pressure, iris rubeosis, type 2 diabetes mellitus.

Библиографические ссылки

1. Simha A, Braganza A, Abraham L, et al. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database of Systematic Reviews. 2020;2:CD007920.

2. Havens SJ, Gulati V. Neovascular glaucoma. Developments in Ophthalmology. 2016; 55:196–204.

3. Zhou M, Wang W, Huang W, Zhang X. Trabeculectomy with versus without adjunctive bevacizumab in neovascular glaucoma: a meta-analysis. BMC Ophthalmology. 2016;16(1):121.

4. Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Seminars in Ophthalmology. 2009;24(2):113–121.

5. Rodrigues GB, Abe RY, Zangalli C, et al. Neovascular glaucoma: a review. International Journal of Retina and Vitreous. 2016;2:26.

6. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Archives of Ophthalmology. 1985;103(12):1796–1806.

7. Aquino MC, Barton K, Tan AM, et al. Micropulse versus continuous wave transscleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study. Clinical and Experimental Ophthalmology. 2015;43(1):40–46.

8. Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. Journal of Glaucoma. 2009;18(8):632–637.